Insilico Medicine develops a new approach to concomitant cancer immunotherapy
IMAGE: This is the Insilico Medicine logo. view more Credit: Insilico Medicine Summary: Some of the most promising drugs for cancer therapy called checkpoint inhibitors often result in complete remissions, however, a majority of patients fail cancer immunotherapy with antibodies targeting immune checkpoints, such as CTLA-4 or programmed death-1 (PD-1). Insilico Medicine developed a set of pathway-based signatures of response to popular checkpoint inhibitors Using these markers and a deep learned drug scoring engine Insilico Medicine identified 12 leads that may help increase response to cancer immunotherapy and is seeking industry partnerships to test these leads Thursday, July 14, 2016, Baltimore, MD — Recent advances in cancer immunotherapy demonstrated complete remission in multiple tumor types including melanoma and lung cancers. Almost every major pharmaceutical company operating in oncology space started multiple…
Link to Full Article: Insilico Medicine develops a new approach to concomitant cancer immunotherapy
Insilico Medicine develops a new approach to concomitant cancer immunotherapy
